Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/6/2022 | $3.00 → $1.00 | Neutral → Underweight | Piper Sandler |
| 3/9/2022 | $11.00 → $6.00 | Buy | Citigroup |
| 3/2/2022 | $5.00 → $3.00 | Neutral | Piper Sandler |
| 3/2/2022 | $5.00 → $2.00 | Equal-Weight → Underweight | Barclays |
| 12/16/2021 | $7.00 → $5.00 | Equal-Weight | Barclays |
| 8/31/2021 | $10.00 → $3.00 | Overweight → Neutral | Piper Sandler |
| 8/9/2021 | $6.00 → $5.00 | Sector Perform | RBC Capital |
MONTREAL, June 12, 2023 /CNW/ - C3i Center Inc and Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ:ENDP), have partnered to launch a complimentary clinical testing program for the diagnosis of the T315I mutation in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) patients in Canada. "We're pleased to be working with Paladin Labs to offer this innovative and important testing program that will provide physicians and patients with additional information to guide treatment decisions," says Dr Lambert Busque, Chief Medical Officer of C3i. "Digital PCR (ddPCR) technology can identify the T315I mutation with a sensitivit
MONTREAL, June 12, 2023 /PRNewswire/ - C3i Center Inc and Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ:ENDP), have partnered to launch a complimentary clinical testing program for the diagnosis of the T315I mutation in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) patients in Canada. "We're pleased to be working with Paladin Labs to offer this innovative and important testing program that will provide physicians and patients with additional information to guide treatment decisions," says Dr Lambert Busque, Chief Medical Officer of C3i. "Digital PCR (ddPCR) technology can identify the T315I mutation with a sen
Sale Transaction Would Result in a Substantial Reduction of Debt and Contemplates Purchaser-Established Voluntary Trusts Funded with $550 Million to Benefit Opioid Claimants Patients and Customers Will Continue to Receive Highest Quality Products and Excellent Service Ample Liquidity to Fund Day-to-Day Operations and Ordinary Course Investments During Court-Supervised Process DUBLIN, Aug. 16, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) ("Endo" or the "Company") today announced that it has entered into a restructuring support agreement ("RSA") with holders of more than a majority of Endo's first lien debt on a sale transaction that would substantially reduce outstanding indebted
DUBLIN, May 5, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter 2022 financial guidance. "Despite challenging market dynamics for VASOSTRICT®, our first-quarter financial performance was in-line with our expectations with growth in our Branded Specialty Products portfolio driven by XIAFLEX® and our Generics segment driven by varenicline, the only FDA approved generic for Chantix®," said Blaise Coleman, Endo's President and Chief Executive Officer. "As we manage thro
DUBLIN, May 2, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc. "These six product candidates that would be used in critical care settings meaningfully expand Endo's ready-to-use injectable product pipeline," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "We look forward to further developing and bringing these durabl
DUBLIN, April 12, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) will announce its first–quarter 2022 financial results on May 5, 2022 and members of its senior management team will host a conference call and webcast on May 6, 2022 at 7:30am ET before the U.S. financial markets open. The dial-in number to access the call is U.S./Canada (866) 497-0462, International (678) 509-7598, and the passcode is 8947159. Please dial in 10 minutes prior to the scheduled start time. A replay of the call will be available from May 6, 2022 at 10:30 a.m. ET until 9:30 a.m. ET on May
DUBLIN, Jan. 11, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today announced the appointment of Dr. James P. Tursi as Executive Vice President, Global Research & Development effective January 18, 2022. He will join the Company's Senior Executive Team and report directly to the Chief Executive Officer. Prior to joining Endo, Dr. Tursi held the role of Chief Scientific Officer and Executive Vice President of Development at Ferring Pharmaceuticals U.S. "Dr. Tursi is a proven leader with nearly 20 years in the pharmaceutical industry and over 30 total years of medical experience," said Blaise Coleman, Endo's President and Chief Executive Officer. "His broad therapeutic expertis
DUBLIN, Feb. 17, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately. Ms. Chao has also been appointed to Endo's Audit Committee and its Compliance Committee and becomes the eighth independent director on Endo's expanded ten member Board. Ms. Chao will stand for election by Endo's shareholders at the Company's 2021 Annual General Meeting. Continue Reading Jennifer M. Chao Ms. Chao has over 25 years of experience in the biotech and life sciences industries focused primarily on finance and corporate strategy. She is the founder
Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour join POINT’s Board of Directors TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced the appointment of Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour to its Board of Directors. Mr. Goodman was the co-founder, President and CEO of publicly-traded Paladin Labs Inc (TSE:PLB), which was acquired in 2014 by Endo International Inc. (NASDAQ:ENDP) for $3.2 billion. The same day that Paladin was sold, Mr. Goodman started a second publicly-traded specialty pharmaceutical company, Kn
8-K - Endo International plc (0001593034) (Filer)
8-K - Endo International plc (0001593034) (Filer)
8-K - Endo International plc (0001593034) (Filer)
SC 13G - Endo International plc (0001593034) (Subject)
SC 13G - Endo International plc (0001593034) (Subject)
SC 13G - Endo International plc (0001593034) (Subject)
4 - Endo International plc (0001593034) (Issuer)
4 - Endo International plc (0001593034) (Issuer)
4 - Endo International plc (0001593034) (Issuer)
Piper Sandler downgraded Endo Intl from Neutral to Underweight and set a new price target of $1.00 from $3.00 previously
Citigroup reiterated coverage of Endo International with a rating of Buy and set a new price target of $6.00 from $11.00 previously
Piper Sandler reiterated coverage of Endo International with a rating of Neutral and set a new price target of $3.00 from $5.00 previously
https://twitter.com/ZekeJMiller/status/1570831511469060096
Gainers Minerva Neurosciences (NASDAQ:NERV) stock rose 30.1% to $5.87 during Tuesday's after-market session. Trading volume for this security closed at 1.6 million, accounting for 158.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $31.3 million. NantHealth (NASDAQ:NH) shares increased by 10.54% to $0.47. The market value of their outstanding shares is at $54.1 million. Regulus Therapeutics (NASDAQ:RGLS) shares rose 8.6% to $1.64. The market value of their outstanding shares is at $24.0 million. Seer (NASDAQ:SEER) stock increased by 7.79% to $10.78. The market value of their outstanding shares is at $674.9 million. Talkspace (
Gainers AnPac Bio-Medical Science (NASDAQ:ANPC) shares increased by 90.9% to $0.41 during Monday's regular session. Trading volume for this security as of 13:30 EST is 78.6 million, which is 12691.0% of its average full-day volume over the last 100 days. The company's market cap stands at $16.2 million. Minerva Neurosciences (NASDAQ:NERV) shares increased by 46.53% to $4.55. As of 13:30 EST, Minerva Neurosciences's stock is trading at a volume of 12.7 million, which is 1639.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $24.2 million. Summit Therapeutics (NASDAQ:SMMT) shares increased by 42.72% to $1.57. Trading volume for